Abstracts tagged "Lupus"

Abstract Number: 2895 • 2013 ACR/ARHP Annual Meeting
Bacterial Amyloids Promote Type I Interferon Production and Accelerate Autoimmunity
Paul Gallo, Glenn Rapsinski, Cagla Tukel and Stefania Gallucci, Dept. of Microbiology and Immunology, Laboratory of Dendritic Cell Biology, Temple Autoimmunity Center, Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Infection is a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). This is largely due to the use of…
Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting
Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Joan T. Merrill¹, Frederick W. Immermann², Tianhui Zhou³, Margot O'Toole⁴, Maryann Whitley⁵, Andrew A. Hill⁵, Ying Zhang⁵, David von Schack⁵, Padmalatha S. Reddy⁵, Jaime L. Masferrer⁴, Stan Kamp¹, Joel M. Guthridge⁶, Aikaterini Thanou⁷, Paul Wu⁵, Theresa Paradis⁵, William M. Mounts⁵, Judith A. James⁸ and Sudhakar T. Sridharan², ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ³BioTherapeutics R&D, Bristol Myers Squibb, Princeton, NJ, ⁴independent consultant, Cambridge, MA, ⁵Pfizer Inc, Cambridge, MA, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immmunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…
Abstract Number: 890 • 2013 ACR/ARHP Annual Meeting
Quantitative Cell Distance Mapping In Human Nephritis Reveals Organization Of In Situ Adaptive Immune Responses
Marcus R. Clark¹, Vladimir M. Liarski¹, Natalya Kavernia², Maryellen L. Giger³, Anthony Chang⁴, Yahui Peng³ and Daniel F. Brandt², ¹Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²Rheumatology, University of Chicago, Chicago, IL, ³Radiology, University of Chicago, Chicago, IL, ⁴Pathology, University of Chicago, Chicago, IL
Background/Purpose: Inflammatory infiltrates contain multiple cell types that could interact in myriad ways to amplify in situ immune responses. However, there currently are no methods…
Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting
Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Silvio M. Vieira¹, Andrew Yu¹, Odelya E. Pagovich¹, Eleni Tiniakou², John Sterpka¹ and Martin A. Kriegel^3,4, ¹Yale School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
Abstract Number: 2890 • 2013 ACR/ARHP Annual Meeting
Novel Selective Inhibitors Of Nuclear Export (SINE) Decrease Type I Interferon Activation and Deplete Autoreactive Plasma Cells In The Kidney In Murine Lupus
Teresa Owen¹, Javier Rangel-Moreno², Boris Klebanov³, Yosef Landesman³, Michael Kauffman³, Sharon Shacham³ and Jennifer H. Anolik⁴, ¹Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ³Karyopharm Therapeutics Inc., Natick, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: There is great interest in developing new treatment approaches for SLE, but the biologic therapies under investigation over the past several years have yielded…
Abstract Number: 1624 • 2013 ACR/ARHP Annual Meeting
Lupus Risk Alleles With High Ethnic Variability Worldwide Are Associated With Renal Disease In Hispanic Patients
Belinda Waltman¹, Kimberly E. Taylor², Joanne Nititham³ and Lindsey A. Criswell³, ¹Department of Medicine, University of California, San Francisco, San Francisco, CA, ²Department of Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately affects minority patients. Non-European ancestry is associated with more severe disease, and conversely, European ancestry is associated with a…
Abstract Number: 905 • 2013 ACR/ARHP Annual Meeting
Lupus and Reproductive Health Considerations: A Pilot Training For Reproductive Health Care Providers Serving Teens and Young Adults
Shawn Rose¹, Dariana M. Pichardo², Monica C. Richey³, Josephine Isgro⁴ and Roberta Horton⁵, ¹Cardiovascular and Pulmonary Branch, NIAMS, NHLBI, Bethesda, MD, ²Department of Social Work Programs, Hospital For Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University Medical Center, New York, NY, ⁵Department of Social Work Programs, Hospital for Special Surgery, New York, NY
Background/Purpose: Health disparities (our target communities continue to experience some of the highest rates of sexually transmitted disease and teen pregnancy in the country) related…
Abstract Number: 561 • 2013 ACR/ARHP Annual Meeting
Acyl-CoA Synthetase 1 Expression Is Increased In Murine Models Of Lupus As Well As In Human Systemic Lupus Erythematosus
Eyal Kedar¹, Shelley Barnhart², Keith B. Elkon³ and Karin Bornfeldt², ¹Rheumatology, University of Washington, Seattle, WA, ²Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, ³Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: The enzyme acyl-CoA synthetase 1 (ACSL1) converts free fatty acids into their biologically active acyl-CoA derivatives. It is induced by lipopolysaccharide and cytokines (including…
Abstract Number: 2897 • 2013 ACR/ARHP Annual Meeting
The Risk Of Deep Vein Thrombosis and Pulmonary Embolism In Systemic Lupus Erythematosus: A Population-Based Cohort Study
J. Antonio Avina-Zubieta¹, Eric C. Sayre², Diane Lacaille^1,3 and John M. Esdaile⁴, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Previous hospital-based studies have shown that patients with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease, but limited population-based data are…
Abstract Number: 1605 • 2013 ACR/ARHP Annual Meeting
Post-Marketing Experience With Belimumab In U.S. Lupus Centers: Data From The Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry
Jinoos Yazdany¹, Doruk Erkan², Jorge sanchez-Guerrero³, Bevra H. Hahn⁴, Alana B. Levine², Galina Marder⁵, W. Joseph McCune⁶ and Ellen M. Ginzler⁷, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine, North Shore Long Island Health System, Great Neck, NY, ⁶Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁷Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: Much of the published experience with belimumab in lupus patients has derived from clinical trials. We examined the non-sponsored experience with belimumab in routine…
Abstract Number: 849 • 2013 ACR/ARHP Annual Meeting
Reasons For Failure To Obtain Influenza and Pneumococcal Vaccines Among Immunosuppressed Individuals With Systemic Lupus Erythematosus
Erica F. Lawson¹, Laura Trupin², Emily von Scheven³, Edward H. Yelin² and Jinoos Yazdany², ¹Pediatrics, University of California, San Francisco, San Francisco, CA, ²Medicine, UC San Francisco, San Francisco, CA, ³Pediatrics, UC San Francisco, San Francisco, CA
Background/Purpose: Infection is the third-leading cause of death in individuals with systemic lupus erythematosus (SLE) in developed countries. Nearly half of those deaths are attributed…
Abstract Number: 541 • 2013 ACR/ARHP Annual Meeting
An Essential Role For Caspase-1 In The Induction Of Murine Lupus and Its Associated Vascular Damage
J. Michelle Kahlenberg¹, Srilakshmi Yalavarthi², Wenpu Zhao², Jeffrey Hodgin³, Tamra J. Reed⁴, Noriko M. Tsuji⁵ and Mariana J. Kaplan⁶, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Department of Pathology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ⁵3Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan, ⁶Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune syndrome associated with organ damage and an elevated risk of cardiovascular disease (CVD) resulting from activation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.